in Health care
Cipla joins hands with Novartis Pharma AG to market diabetes drug Galvus in India
Mumbai: Pharma major, Cipla Limited, has announced that it has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from 1st January 2026. The agreement is subject to satisfaction of certain conditions precedent, Cipla informed. “During the […] More
